The authors have no funding, financial relationships, or conflicts of interest to disclose.
Head and Neck
A double-blind study on clonazepam in patients with burning mouth syndrome†
Article first published online: 16 FEB 2012
Copyright © 2011 The American Laryngological, Rhinological, and Otological Society, Inc.
Volume 122, Issue 4, pages 813–816, April 2012
How to Cite
Heckmann, S. M., Kirchner, E., Grushka, M., Wichmann, M. G. and Hummel, T. (2012), A double-blind study on clonazepam in patients with burning mouth syndrome. The Laryngoscope, 122: 813–816. doi: 10.1002/lary.22490
- Issue published online: 20 MAR 2012
- Article first published online: 16 FEB 2012
- Accepted manuscript online: 6 DEC 2011 03:52AM EST
- Manuscript Accepted: 17 NOV 2011
- Manuscript Revised: 15 NOV 2011
- Manuscript Received: 31 OCT 2011
- Level of Evidence: 1b
In the treatment of burning mouth syndrome (BMS), various approaches have been tried with equivocal results. The aim of the present randomized clinical trial was to determine the efficacy of clonazepam, a GABA agonist designed as an antiepileptic drug that exerts the typical effects of benzodiazepines.
Randomized clinical trial.
Twenty patients with idiopathic BMS were carefully selected. Clonazepam (0.5 mg/day, n = 10) or placebo (lactose, n = 10) were randomly assigned to the patients.
Patients on clonazepam significantly improved in pain ratings (P < .001). These changes were less pronounced in the placebo group (P < .11). No significant changes were observed in a mood scale (P = .56) or for depression scores (P = .56). Taste test and salivary flow increased over sessions, but were not different between groups (P = .83 and P = .06, respectively).
Clonazepam appears to have a positive effect on pain in BMS patients. Laryngoscope, 2012